A case of severe bilateral corneal ulcer associated with sintilimab therapy: case report and literature review
Frontiers in Pharmacology · 14.07.2026 · 17
DOI: 10.3389/fphar.2026.1857433 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.07.2026. Verfasst von Lei Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors, including PD-1 inhibitors such as sintilimab, have revolutionized cancer treatment but may induce immune-related adverse events (irAEs). Ocular irAEs, particularly severe corneal complications, are increasingly recognized but remain underreported, especially with sintilimab.
Methods
We report a case of a patient in their 60 s with gastric adenocarcinoma who developed bilateral severe corneal ulcers following sintilimab therapy. A comprehensive review of literature on PD-1/PD-L1 inhibitor-associated corneal lesions was conducted to contextualize this rare complication.
Results
The patient presented with progressive ocular symptoms 3 weeks after initiating sintilimab. Despite topical anti-inflammatory and antimicrobial treatment, bilateral corneal ulcers progressed, culminating in corneal perforation of the right eye. Conservative medical management led to gradual healing and anterior chamber reformation. Literature review identified few similar cases, highlighting the rarity and severity of sintilimab-associated corneal toxicity.
Conclusion
This case underscores the potential for severe, vision-threatening corneal complications following PD-1 inhibitor therapy. Early recognition, interdisciplinary collaboration, and timely intervention are critical to mitigate ocular morbidity. Ophthalmologists and oncologists should maintain high vigilance for ocular irAEs in patients receiving immune checkpoint inhibitors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Beijing Tsinghua ChangGung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, L., Zhang, C., Si, S., Wang, J., & Liu, X. (2026). A case of severe bilateral corneal ulcer associated with sintilimab therapy: case report and literature review. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1857433
Vancouver
Wang L, Zhang C, Si S, Wang J, Liu X. A case of severe bilateral corneal ulcer associated with sintilimab therapy: case report and literature review. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1857433
BibTeX
@article{Wang2026,
author = {Wang, Lei and Zhang, Chun and Si, Shancheng and Wang, Junyi and Liu, Xuan},
title = {A case of severe bilateral corneal ulcer associated with sintilimab therapy: case report and literature review},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1857433}
}
EUVIMED